article thumbnail

Nitrosamine contamination in medicines: risk, regulation and reality

Hospital Pharmacy Europe

Nitrosamines are a class of chemical compounds formed via nitrosation – the reaction of a nitroso group (–NO) with an amine. This included antibiotics such as erythromycin and tetracyclines and other compounds such as imipramine. N-Nitroso compound contaminants in prescription and non-prescription drugs. 3 Krull I et al.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

December 21, 2004. PR Newswire. June 10, 2025. Accessed June 10, 2025. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diabetes Risk Reduction Practices Low for Women With Gestational Diabetes

Drug Topics

They included patients from a large regional hospital in northern Victoria, Australia, who attended the diabetes center from July 2004 to July 2005 for the management of gestational diabetes. The pilot study was aimed at determining diabetes risk reduction behavior when achieving a healthy weight and being physically active.

article thumbnail

STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices

STAT

Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.

FDA
article thumbnail

Health Innovators: Owlstone Medical’s Billy Boyle on breath biopsy technology

pharmaphorum

Owlstone is developing a breath-based analyser that captures Volatile Organic Compounds (VOCs) in breath non-invasively, and analyses them with high sensitivity. After studying engineering at Cambridge University, Boyle founded Owlstone Inc in 2004 with a focus on sensor technology for military and industrial applications.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

4,6 Traditional Herbal Registration The Traditional Herbal Medicines Directive (Directive 2004/24/EC) is implemented in the UK by the Medicines (Traditional Herbal Medicinal Products for Human Use) Regulations 2005 and came into force on 30 April 2011. 13 Currently, over 350 herbal remedies have been granted a THR licence. 2012/1916).

FDA